Baba Ishfaq Ahmad, Wani Zubair Ahmad, Mubarak Mohamad Mosa, Ahmad Zahoor
Clinical Microbiology and PK-PD Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, J&K, 190005, India.
Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
Extremophiles. 2025 Aug 1;29(2):33. doi: 10.1007/s00792-025-01398-y.
The rise of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis (M. tb) has driven the search for new antimycobacterial agents. Our study focused on isolation and characterization of actinomycetes from the hypersaline Tso-Kar Salt lake in Ladakh, India, to explore their antibacterial potential. We isolated 145 bacterial isolates from various soil, salt and water samples and found 23 actinomycete isolates effective against Mycobacterium smegmatis through cross-streak screening. Molecular identification confirmed that these isolates belonged to 14 genera of actinomycetes. Out of 23 extracts from these isolates, 15 ethyl acetate organic extracts exhibited strong antimycobacterial activities against M. smegmatis, M. tb H37Ra, and M. tb H37Rv, with MIC values between 125 and 31.25 µg/mL. Importantly, all 15 extracts demonstrated bactericidal activities at their respective MICs against M. tb H37Rv. The other 8 extracts displayed comparatively weaker MIC and MBC ranging 500-250 µg/mL and 1000-500 µg/mL respectively. These extracts were equally effective against drug-resistant and drug-susceptible M. tb clinical isolates. Furthermore, they showed broad antibacterial activity against both gram-positive and gram-negative bacteria, with MICs ranging from 500 to 31.25 µg/mL. The GC-MS analysis of the potent extracts revealed that a wide range of compounds including Phenolics, Peptides, Ergot alkaloids and their derivates may have contributed to anti-mycobacterial activity. The genetic diversity and significant antimicrobial properties of these actinomycetes from extreme environments highlight their potential for developing new antituberculosis and general antibiotic agents, particularly against MDR infections.
结核分枝杆菌多重耐药(MDR)菌株的出现推动了新型抗分枝杆菌药物的研发。我们的研究聚焦于从印度拉达克超盐湖措卡湖分离和鉴定放线菌,以探索其抗菌潜力。我们从各种土壤、盐和水样中分离出145株细菌,通过交叉划线筛选发现23株放线菌对耻垢分枝杆菌有效。分子鉴定证实这些分离株属于14个放线菌属。在这些分离株的23种提取物中,15种乙酸乙酯有机提取物对耻垢分枝杆菌、结核分枝杆菌H37Ra和结核分枝杆菌H37Rv表现出较强的抗分枝杆菌活性,最低抑菌浓度(MIC)值在125至31.25μg/mL之间。重要的是,所有15种提取物在各自的MIC浓度下对结核分枝杆菌H37Rv均表现出杀菌活性。另外8种提取物的MIC和最低杀菌浓度(MBC)相对较弱,分别为500 - 250μg/mL和1000 - 500μg/mL。这些提取物对耐药和敏感的结核分枝杆菌临床分离株同样有效。此外,它们对革兰氏阳性菌和革兰氏阴性菌均表现出广泛的抗菌活性,MIC范围为500至31.25μg/mL。对有效提取物的气相色谱 - 质谱(GC - MS)分析表明,包括酚类、肽类、麦角生物碱及其衍生物在内的多种化合物可能对抗分枝杆菌活性有贡献。这些来自极端环境的放线菌的遗传多样性和显著的抗菌特性凸显了它们在开发新型抗结核和通用抗生素药物,特别是针对MDR感染方面的潜力。